IntraLinks, a provider of critical information exchange solutions, announced a strategic partnership with Adobe Systems Inc., to develop automated solutions addressing cross-organization data capture and submission based-business processes within the life sciences industry. Specifically, the joint solution is aimed to improve workflow during the site recruitment and study start-up phases of a clinical trial.
Once an electronic form is created using Adobe’s LiveCycle Enterprise Suite (ES), IntraLinks' validated platform manages the external workflow to organize, distribute, collect, and track e-forms across the firewall with email notifications and a "one-click to submit" process. LiveCycle ES completes the process by automatically retrieving the completed forms from IntraLinks and routing them through an internal review and approval process.
“Building on Adobe's LiveCycle ES, IntraLinks will leverage its secure and auditable information exchange platform to create a truly paperless solution for the clinical trials process," said Alison Shurell, vice president, IntraLinks, said in a press release. "This new platform replaces inefficient and non-secure methods of sharing sensitive clinical trial documents such as email, fax and courier."
"Life sciences professionals who already depend on Adobe's LiveCycle ES for data capture and submission based processes will now have a comprehensive solution for document-centric workflows," said Melonie Warfel, Director Worldwide Standards & Life Sciences for Adobe Systems Inc. "Together, Adobe and IntraLinks will work to make clinical trial management an efficient, paper-free process." IntraLinks provides on-demand solutions for businesses in various industries to securely collaborate, communicate and exchange critical information inside and outside the enterprise. For more information on Adobe’s LiveCycle ES for Life Sciences, link here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.